Myeloma Crowd Radio/MCRI: Dr. Carmen Baldino, PhD and Dr. Kelvin Lee, MD
Play • 1 hr 2 min
Patients who have high-risk genetic features like the 14;16 translocation need new treatment options. Dr. Carmen Baldino of Jasco Pharmaceuticals and Dr. Kelvin Lee of the Roswell Park Cancer Institute are working on a potentially curative solution for patients with this high-risk translocation using a PIM2 Kinase inhibitor called JP-11646. Learn more about this proposal for the Myeloma Crowd Research Initiative to address the unmet needs for high-risk patients.
More episodes
Clear search
Close search
Google apps
Main menu